- National Highway construction slows to 20.43 km per day in first 4 months of current fiscal
- Independence Day Special: How investment habits, preferences of people have changed over the past 75 years
- BMW M4 Competition Coupé 50 Jahre M Edition: Price and features | Photos
- Financial Independence for Women: top investment tips for the other half to make them independent moneywise
Bharat Biotech
Covid-19: Bharat Biotech's Covaxin, Serum Institute's Covishield vaccines get 'Conditional Market Authorization' approval form DCGI - details here!
Thu, Jan 27, 2022
DCGI on Thursday gave its nod for market authorization of two COVID-19 vaccines - Covaxin and Covishield subject to certain conditions. Consent came after the the Subject Expert Committee of CDSCO recommended for upgradation of status for vaccines from restricted use in emergency situations to grant of new drug permission
More >
Covid19: After getting regular market approval, each dose of Covishield, Covaxin likely to cost this
Wed, Jan 26, 2022
The price of Covaxin is at Rs 1,200 per dose as of now while Covishield costs Rs 780 in private facilities. The prices include Rs 150 service charge. Both the vaccines are only authorised for emergency use in the country
More >
Covid 19: Decision on emergency use listing of Bharat Biotech's Covaxin likely in 4-6 weeks: WHO
Sat, Jul 10, 2021
The World Health Organization (WHO) is likely to take a decision on including Bharat Biotech's COVID-19 vaccine Covaxin in the emergency use list (EUL) within four to six weeks, Soumya Swaminathan, the global health body's chief scientist has said.
More >
CONFIDENCE BOOSTER! Covaxin 93.4% effective against severe symptomatic COVID-19 cases, 65.2% against new Delta variant, says Bharat Biotech
Sat, Jul 03, 2021
Bharat Biotech has released safety and efficacy analysis data from Phase III clinical trials of COVAXIN®, a whole virion inactivated vaccine against SARS-CoV2.
More >
Bharat Biotech's Covaxin efficacy results in Phase III trials: REVEALED!
Tue, Jun 22, 2021
Bharat Biotech's Covaxin has shown 77.8 percent efficacy after the Subject Expert Committee (SEC) under the drug regulator reviewed its Phase III trials data on Tuesday, according to sources, as per ANI.
More >
Hester has signed a drug substance production agreement with Bharat Biotech: Rajiv Gandhi, CEO & MD
Fri, Jun 18, 2021
Rajiv Gandhi, CEO & Managing Director, Hester Biotech Limited, talks about March quarter performance, Covaxin and tie-up with Bharat Biotech, the international business among others during a chat with Swati Khandelwal, Zee Business.
More >
From Bharat Biotech Covaxin, AstraZeneca/Oxford/ Serum Institute' Covishield and much more: EXPLAINED
Mon, Jan 04, 2021
Bharat Biotech's Covaxin is an exception as it is still in Phase-3 and yet to complete trial recruitment. No interim analysis of efficacy is available and pre-print Phase-1/2 data have only given details on immunogenicity and not efficacy of the vaccine. The emergency use approval, even as a back-up vaccine, is therefore highly unusual. Government authorities have announced that Serum's Covishield will remain the primary vaccine for the time being and Bharat Biotech's Covaxin will be in back-up, only to be used in case of a surge in case.
More >
This Covid-19 vaccine safest with less allergic reactions - Bharat Biotech reveals
Mon, Dec 21, 2020
Covid-19 vaccine: Bharat Biotech has claimed that amongst all the vaccine platforms such as an mRNA-based vaccine, DNA-based vaccine, vector-based vaccine, or live attenuated vaccines, etc., the inactivated vaccines being developed by it for Covid 19 are safest, and hence, the adverse reactions are lesser.
More >
